Contents

Search

ertugliflozin (Steglatro)

Indications: - treatment of diabetes mellitus type 2 - cardiovascular risk reduction or not [5] Dosage: - start: 5 mg PO QAM; may increase to 15 mg PO QD Tabs: 5-mg, 15-mg Adverse effects: - diabetic ketoacidosis, fracture risk, acute renal failure. increased risk of toe amputation (class effects, rare) Mechanism of action: - inhibition of SGLT2, glycosuric Notes: - FDA-approved Dec 2017 [1] - Generic FDA-approved 2023 [6]

Interactions

drug adverse effects of hypoglycemic agents

General

SGLT-2 inhibitor; oral glucosuric agent; flozin

References

  1. Busko M FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes Medscape - Dec 21, 2017. https://www.medscape.com/viewarticle/890446 - Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871 - U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  2. Terra SG, Focht K, Davies M et al Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May;19(5):721-728. Epub 2017 Feb 22. PMID: 28116776
  3. Rosenstock J, Frias J, Pall D et al Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017 Aug 31. [Epub ahead of print] PMID: 28857451
  4. Dagogo-Jack S, Liu J, Eldor R et al Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo- controlled randomized study. Diabetes Obes Metab. 2017 Sep 17. [Epub ahead of print] PMID: 28921862
  5. Cannon CP et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020 Sep 23; [e-pub]. PMID: 32966714 https://www.nejm.org/doi/10.1056/NEJMoa2004967
  6. ACP Diabetes Monthly Newsletter. November 10, 2023